NCMAG107 Dabrafenib plus trametinib advice document: October 2023
Posted on:
Document Type
Process guidance
Summary
Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options. (Off-label use)
Decision: supported